ProfileGDS5678 / 1459159_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 32% 33% 32% 34% 33% 31% 30% 38% 33% 33% 33% 32% 33% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7534832
GSM967853U87-EV human glioblastoma xenograft - Control 22.7471833
GSM967854U87-EV human glioblastoma xenograft - Control 32.722232
GSM967855U87-EV human glioblastoma xenograft - Control 42.7197434
GSM967856U87-EV human glioblastoma xenograft - Control 52.6999233
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7713431
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7425430
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8530438
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7278433
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7439533
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7419733
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6889832
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.742533
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7127532